The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center

Significant advances in multiple myeloma (MM) over the past 15 years led to exciting changes in the management of MM patients in China, which in turn brought about the early diagnoses, precise risk stratifications, and improved prognoses.

[1]  Peng Liu,et al.  The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse , 2023, Cancer.

[2]  S. Jagannath,et al.  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. , 2022, The New England journal of medicine.

[3]  Shuohua Chen,et al.  Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China. , 2022, Cancer epidemiology.

[4]  Shaji K. Kumar,et al.  Current approaches to management of newly diagnosed multiple myeloma , 2022, American journal of hematology.

[5]  Tianhong Xu,et al.  Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value , 2021, Annals of Hematology.

[6]  Z. Cai,et al.  Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma , 2021, Frontiers in Oncology.

[7]  E. Wood,et al.  Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR) , 2021, Bone Marrow Transplantation.

[8]  M. Dimopoulos,et al.  Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.

[9]  B. Barlogie,et al.  Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) , 2020, Blood Cancer Journal.

[10]  U. Mellqvist,et al.  Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud , 2020, The Lancet. Haematology.

[11]  Limei Xu,et al.  Education level as a predictor of survival in patients with multiple myeloma , 2020, BMC Cancer.

[12]  P. Liu,et al.  The impact on early diagnosis and survival outcome of M-protein screening-driven diagnostic approach to multiple myeloma in China: a cohort study , 2019, Journal of Cancer.

[13]  B. Barlogie,et al.  Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) , 2018, Blood Cancer Journal.

[14]  M. Kersten,et al.  Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial , 2018, Leukemia.

[15]  Michael L. Wang,et al.  Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. , 2016, Blood.

[16]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[17]  M. Dimopoulos,et al.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[19]  J. Hou,et al.  Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis , 2014, Blood Cancer Journal.

[20]  M. Kersten,et al.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[22]  C. Pascutto,et al.  Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[24]  W. Jędrzejczak,et al.  Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[26]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[27]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.